Cargando…

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment

BACKGROUND: Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, remains an important public health issue in many Central and South American countries, as well as non-endemic areas with high rates of immigration from these countries. Existing treatment options for CD are limited and often...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santamaria, Cynthia, Chatelain, Eric, Jackson, Yves, Miao, Qianqian, Ward, Brian J, Chappuis, François, Ndao, Momar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059459/ https://www.ncbi.nlm.nih.gov/pubmed/24894358 http://dx.doi.org/10.1186/1471-2334-14-302

Ejemplares similares

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole
por: Ruiz-Lancheros, Elizabeth, et al.
Publicado: (2018)

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice
por: Golizeh, Makan, et al.
Publicado: (2022)

Identification of Candidate Serum Biomarkers for Schistosoma mansoni Infected Mice Using Multiple Proteomic Platforms
por: Kardoush, Manal I., et al.
Publicado: (2016)

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
por: Olivera, Mario Javier, et al.
Publicado: (2015)

Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox
por: Vergara, Camilo, et al.
Publicado: (2019)

Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging
por: Golizeh, Makan, et al.
Publicado: (2018)

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

A family cluster of Chagas disease detected through selective screening of blood donors: A case report and brief review
por: Mongeau-Martin, Guillaume, et al.
Publicado: (2015)

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina
por: Vizcaya, David, et al.
Publicado: (2021)

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020)

Trypanosoma cruzi Infection and Host Lipid Metabolism
por: Miao, Qianqian, et al.
Publicado: (2014)

Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults
por: Falk, N., et al.
Publicado: (2022)

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
por: Rivero, Rocio, et al.
Publicado: (2023)

Successful treatment of suspected early form of chronic Chagas cardiomyopathy: a case report
por: Lu, Nelson, et al.
Publicado: (2022)

Development and Application of an ELISA Assay Using Excretion/Secretion Proteins from Epimastigote Forms of T. cruzi (ESEA Antigens) for the Diagnosis of Chagas Disease
por: Berrizbeitia, Mariolga, et al.
Publicado: (2012)

Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland
por: Jackson, Yves, et al.
Publicado: (2018)

Nifurtimox Inhibits the Progression of Neuroblastoma in vivo
por: Kong, Eryan, et al.
Publicado: (2019)

Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
por: Muñoz, Gabriela, et al.
Publicado: (2019)

Congenital Transmission of Chagas Disease in Latin American Immigrants in Switzerland
por: Jackson, Yves, et al.
Publicado: (2009)

Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia
por: Bianchi, Fiorella, et al.
Publicado: (2015)

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox
por: Lang, Dieter, et al.
Publicado: (2022)

Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure
por: Francisco, Amanda Fortes, et al.
Publicado: (2022)

Chagas disease research and development: Is there light at the end of the tunnel?
por: Chatelain, Eric
Publicado: (2016)

Correction to “Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox”
por: Lang, Dieter, et al.
Publicado: (2023)

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)
por: Altcheh, Jaime, et al.
Publicado: (2023)

Diagnosis of Parasitic Diseases: Old and New Approaches
por: Ndao, Momar
Publicado: (2009)

Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021
por: Abbott, Andrew, et al.
Publicado: (2022)

2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study)
por: Jaime, A L T C H E H, et al.
Publicado: (2022)

Negativation of Trypanosoma cruzi PCR within Six Months after Treatment of a Child with Nifurtimox
por: Pull, Lauren, et al.
Publicado: (2015)

Translational challenges of animal models in Chagas disease drug development: a review
por: Chatelain, Eric, et al.
Publicado: (2015)

Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009)

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
por: Du, Michael, et al.
Publicado: (2016)

720. Efficacy of Nifurtimox + Eflornithine in the Treatment of African Trypanosomiasis. Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)

Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites
por: Hall, Belinda S., et al.
Publicado: (2011)

Trypanosoma cruzi Mitochondrial Peroxiredoxin Promotes Infectivity in Macrophages and Attenuates Nifurtimox Toxicity
por: Specker, Gabriela, et al.
Publicado: (2022)

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
por: Altcheh, Jaime, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t4t4sgjl6mb25n5vsvpvb1l9s8